Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans

Diabetes. 2008 Feb;57(2):325-31. doi: 10.2337/db07-1162. Epub 2007 Nov 8.

Abstract

Objective: Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption.

Research design and methods: We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary-pancreatic normoglycemic (plasma glucose approximately 4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer.

Results: On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25-30% in individual gray matter regions (P = 0.02-0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1.

Conclusions: We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Transport / drug effects
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology*
  • Brain / diagnostic imaging
  • Brain / metabolism
  • C-Peptide / blood
  • Double-Blind Method
  • Glucagon-Like Peptide 1 / pharmacology*
  • Glucose / metabolism*
  • Humans
  • Insulin / blood
  • Male
  • Placebos
  • Positron-Emission Tomography
  • Postprandial Period
  • Radiography
  • Recombinant Proteins / pharmacology
  • Reference Values

Substances

  • Blood Glucose
  • C-Peptide
  • Insulin
  • Placebos
  • Recombinant Proteins
  • Glucagon-Like Peptide 1
  • Glucose